Summary The aim of the study was to assess the completeness and accuracy of cancer registration for cutaneous malignant melanoma. The study was conducted in seven health districts in England and one health board in Scotland from 1987 to 1989 with a total resident population of 3.6 million. Records from pigmented lesion clinics and pathology laboratories colected during the Cancer Research Campaign's health education programme to promote the early detection of melanoma were matched with cancer registrations from a total of five regional cancer registries. In England 74% out of a total of 642 cases of invasive malignant melanomas (ICD 172) and 44% out of a total of 155 in situ melanomas (ICD 232) had been registered compared with 96% and 100% respectively in Scotland. A significantly higher proportion of late-stage cases was found among registered than among non-registered cases in England (P<0.001). In all registries the majority of superficial spreading in situ melanomas were miscoded as invasive cases. The annual incidence of invasive malignant melanoma in tie English study areas was found to be seven per 100 000 in men and 1 1 per 100 000 in women, similar to that reported in Scotland. The registries are best at recording thick or late-stage melanomas. As the skin cancer target for Health of the Nation depends on monitoring trends in the incidence of malignant melanoma, future improved ascertainment of cases and changes in the type of cases being registered must be taken into account.
In the government White Paper 'Health of the Nation' a target for skin cancer has been set 'to halt the year-on-year increase in the incidence of skin cancer by 2005' (Department of Health, 1992a) . Monitoring trends in the incidence of non-melanocytic skin cancers (International Classification of Diseases, 9th revision: ICD9) is known to be problematic because of incomplete registration (Roberts, 1992) . In 1993 some English registries ceased registration of basal cell carcinomas.
Although there has undoubtedly been a true increase in the incidence of malignant melanoma (ICD9 172) in England in recent decades, some of the steep rise is likely to be explained by improved ascertainment of cases for registration. Of 20 cases of melanoma occurring from 1968 to 1985 in an English population of 17000 women aged 25-49 years, eight (40%) had not been registered (Villard-Mackintosh et al., 1988) . More recently the Thames Cancer Registry (1994) estimated that 28-31% of malignant melanomas had not been registered, using a calculation based on the distribution of survival, cause of death and chance of being registered from medical records. In contrast, Scotland is believed to have nearly complete registration because of the Scottish Melanoma Group register established in 1979 (MacKie et al., 1992) ; this register, set up by dermatologists, surgeons and pathologists, exchanges information every year with the Scottish Cancer Registries. The higher incidence rates reported in Scotland (7.1 per 100000 and 10.4 per 100000 in males and females respectively) than in England (3.9 per 100000 and 6.1 per 100000 in males and females respectively) (Melia et al., 1994a) for (Table I) . Analysis of invasive malignant melanoma by source showed that overall 173 (22%) cases were identified by the registries alone, 172 (22%) cases by other sources alone and 442 (56%) cases by both. The proportion of cases identified by the registry alone was highest in London (37%), where there is cross-boundary flow of treatment and cases had been treated elsewhere.
In situ melanomas were substantially under-registered in the English areas (44%, range 23-58%) compared with 100% registration in Scotland (Table I) by the cancer registries for the whole of England (six and nine per 100000 in males and females respectively) and the whole of Scotland (nine and 12 per 100000 for males and females respectively).
Dicossio.
The under-registration of malignant melanoma identified in this study has implications for the Health of the Nation target for skin cancer (Department of Health, 1992a) . It has been proposed in the Specifiction of National Indicators for the Health of the Nation (Department of Health, 1992b) that incidence should be monitored separately for both non-melanocytic skin cancers (ICD9 173) and malignant melanoma (ICD9 172). Both clearly suffer from underregistration, and incidence rates can be expected to show an apparent increase in the next few years if ascertainment by the cancer registries improves and if there is increased diagnosis of early-stage, sometimes non-progressive, disease. The cancer registries seem best at recording late-stage malignant melanomas, and therefore ideally the incidence rate of malignant melanoma should be monitored by stage using an index such as Breslow thickness. Breslow thickness has a strong association with prognosis with only 25% of patients with tumours thicker than 3.0mm surviving 5 years compared with 91% of patients with tumours less than 1.51 mm (Breslow, 1970) .
Under-registration of invasive malignant melanoma was low in this study (25%) compared with the 40% reported by Villard-Mackintosh et al. (1988) . Comparisons between the two studies must be made with caution because ascertainment of cases will vary between registries and over time, and also the present study had a much larger population. This study reports on melanomas diagnosed from 1987 to 1989 for the total population in areas covered by four English registries, whereas the other study focused on women aged 25-49 years reporting melanomas from 1968 to 1985. An alternative comparison with the Thames Cancer Registry's own estimate of under-ascertainment for malignant melanoma showed very similar results to those in the CRC study (Thames Cancer Registry, 1994) . Variation in under-registration between registries in part reflects the different methods of data collection used by the registries. Among the English registries registration was highest for the area covered by the Wessex registry, which has established good links with pathology laboratories for several years.
There are two limitations with the data set which may have led to underestimates of the extent of underascertainment. First, it is possible that ascertainment was more complete in the CRC study areas than elsewhere because local dermatological melanoma registers, activities of the health education programme and associated research may have encouraged exchange of information between the hospitals and cancer registries. Second, as it was impractical to collect data from all pathology laboratories diagnosing cases treated outside the study areas, some melanomas may have remained undetected, particularly in areas where pathology links with registries were poor. Thus the ascertainment rate overall in England may be lower than that estimated in this study. On the other hand, the prsence of local registers and research can sometimes hinder cancer registration if, for example, patients' notes are removed for these purposes and thus cannot be foun in the routine searches by registry staff.
Under-ascertaiment is bound to vary between registres across England, and the four English registries may not be representative of all registries. However, the registies had a mix of data collection methods similar to those used elsewhere. Further analysis of the data with respect to stage and patient characteristics (Melia et al., 1995) has shown similarities between the full data set for the study areas and that for the whole of Scotland (MacKie et al., 1992) where there is near complete registration suggestng that there is no substantial bias in the data set presented here.
The under-registration of cancers in England and Wales and various reasons for this are well recognised (Bean et al., 1982; Silcocks et al., 1989) . The important issues arising from the present study are firsty the biases in types of melanomas being registered, which will affect the interpretation of trends in incidence, and secondly errors in the diagnostic coding of in situ cases.
The main bias is the incomplete registration of thin malignant melanomas. As awareness about melanoma increases in the gneral public in Brtain, the number of thin malignant melanomas at diagnosis will also increase (MacKie et al., 1992; Melia et al., 1994b) . Most cases of thin malignant melanoma are treated on an out-patient basis with simple excision, require no further treatment and rarely lead to death. Therefore under-registration of these cases will be high in registries which depend largely on data from in-patient discharge records, radiotherapy departments and death certificates. Therefore pathology laboratories are a very umportant source.
Both the under-registration and bias in type of cases being registered could lead to misinterpretation of geographical variation in incidence rates for malignant melanoma both within the UK and abroad. Asertainment of melanoma cases by registries is believed to be high in areas of Australia where pathology records are used as a source of information (Bonett et al., 1989 ). There has certainly been an increase in the incidence of malignant melanoma in Australia, but some of the rise in parts of Australia may be explained by improved ascertainment (Jones et al., 1992) . In contrast, in one state in USA the under-registration of melanoma cases increased from 2% in 1974 2% in to 21% in 1984 2% in (Karagas et al., 1991 , probably because of increased diagnosis of thin lesions which were not being picked up by the registries.
The problem with the coding of in situ superficial spreading melanomas as invasive may have occurred because of lack of understanding of the use of the matrix system for the coding of such lesions in ICD9 and ICDO. Some confusion may also have been caused by a variety of terms used in clnical records. Thus, in situ supfiial spreading melanomas may not have been recognised as such if the term 'malignant' was used or if 'in situ' was not clearly specified.
Although it will have led to an over-reporting of invasive malignant melanoma, the numbers are too small to have a major impact on estimates of incidence. It is possible that with increased reporting of thin melanomas this could become a sizeable problem. It has also been reported in Australia as a source of error (English et al., 1986) , and a similar coding error has been reported for cervical cancer (Choyce and McAvoy, 1990) . Special studies would help to clarify the extent of this problem for other cancer sites.
In England ascertainment of many cancers will improve as the registries develop linis with pathology laboratories (Codling et al., 1990) . The registries should also be encouraged to record prognostic indice for melanoma as trends in melanomas with a poor prognosis will precede changes in mortality and they are an important marker for improvements in early detection of the disease. Breslow thickness is one of the most reliable measures of prognosis, although there are some probklms with its accuracy (Colloby et al., 1991) . The vertical growth component, which is positively correlated with Breslow thickness, may be a better indicator of prognosis as it requires assessment of two additional components: cytology of the cells and more importantly, the level of invasion of the dermal microenvironment (Clark et al., 1989) . Completeness of these data will depend on both the pathologists and registry staff. The proportion of invasive malignant melanomas for which Breslow depth is routinely measured in England is not known. The completeness of these data (95%) at the pathology laboratories in this study may be higher than that occurring elsewhere if there is no special interest in melanoma. The complteness of data recorded by registry staff does need to be improved as at one registry in this study only 7% of Breslow thicknesses given in the hospital notes had been recorded by the registry.
The main factor affecting the interpretation of trends in incidence of malignant melanoma in England is the underestimate of incidence in young adults and those with thin tumours. As ascertainment continues to improve, some of the apparent increase in incidence seen in the future will reflect this improvement. Incidence rates for malignant melanoma should ideally be monitored by Breslow thickness or stage as registries have been best at recording late-stage cancers and most improvement in ascertaiment is expected for earlystage thin cancers. Inrsed collaboration between pathology laboratories, dermatologists and cancer registries will help to resolve problems with registering melanoma and increasing the recording of data on Breslow thickness.
